Juan Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Juan Wang has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Feng Yue
Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, USA
39 shared publications - Yu Luan
Department of Cell Systems and Anatomy, University of Texas Health Science Center at San Antonio, San Antonio, USA
36 shared publications - Mark W. Youngblood
Northwestern University
35 shared publications - Qixuan Wang
Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine Northwestern University, Chicago, Illinois
35 shared publications - Hongbo Yang
Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine Northwestern University, Chicago, IL, USA
34 shared publications - Lucia Casadei
Comprehensive Cancer Center The Ohio State University Columbus Ohio USA
34 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by Springer Nature in Nature Methods
- Vol. 23 (10) , 2015-2028
Spatial chromatin architecture and accessibility co-profiling of mammalian tissues
Cellular function depends on the spatial organization of cells and biomolecules within the tissue microenvironment. Advances in spatial omics have enabled profiling of molecular features such as transcriptome, proteome and epigenome, and there has been rapid progress of imaging-based approaches to study spatial three-dimensional (3D) genome organization. Here we present Spatial-ATAC-Hi-C, a microfluidic‑based platform for genome-wide, spatially resolved joint-profiling of 3D genome organization and chromatin accessibility on tissue slides. Applied to mouse and human brains, Spatial-ATAC-Hi-C revealed distinct chromatin architecture and gene regulatory programs in neuronal and non-neuronal populations in their native tissue context. In glioblastoma and astrocytoma samples, we detected spatially resolved 3D genome alterations, copy number variations and structural variations across tumor regions, revealing clinically relevant oncogenic events and clonal heterogeneity. By co-profiling of genome architecture and chromatin accessibility while preserving tissue architecture, Spatial-ATAC-Hi-C provides a powerful tool for studying spatial gene regulation in human biology and disease.
- 1 September 2026
- Published by Springer Nature in Nature Methods
- Vol. 23 (10) , 2015-2028
Open AccessSpatial chromatin architecture and accessibility co-profiling of mammalian tissues
Cellular function depends on the spatial organization of cells and biomolecules within the tissue microenvironment. Advances in spatial omics have enabled profiling of molecular features such as transcriptome, proteome and epigenome, and there has been rapid progress of imaging-based approaches to study spatial three-dimensional (3D) genome organization. Here we present Spatial-ATAC-Hi-C, a microfluidic‑based platform for genome-wide, spatially resolved joint-profiling of 3D genome organization and chromatin accessibility on tissue slides. Applied to mouse and human brains, Spatial-ATAC-Hi-C revealed distinct chromatin architecture and gene regulatory programs in neuronal and non-neuronal populations in their native tissue context. In glioblastoma and astrocytoma samples, we detected spatially resolved 3D genome alterations, copy number variations and structural variations across tumor regions, revealing clinically relevant oncogenic events and clonal heterogeneity. By co-profiling of genome architecture and chromatin accessibility while preserving tissue architecture, Spatial-ATAC-Hi-C provides a powerful tool for studying spatial gene regulation in human biology and disease.
- Top Cited PapersOpen Access
- 26 March 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (13) , 1470-1484
Silencing of BCL11A by disrupting enhancer-dependent epigenetic insulation
The transcription factor BCL11A is a genetically and clinically validated regulator of the fetal-to-adult hemoglobin switch in human erythroid cells. CRISPR editing of an intronic enhancer within the BCL11A gene reactivates fetal hemoglobin (HbF) in adult erythroid cells, serving as the first CRISPR-based therapy for β-hemoglobinopathies. However, the molecular basis for the remarkable efficacy of CRISPR-mediated enhancer ablation remains elusive. Here, we describe a new genome architecture, an enhancer-dependent chromatin rosette, that is essential for epigenetic insulation and the developmentally regulated, hematopoietic lineage–specific expression of BCL11A. CRISPR-mediated disruption of the BCL11A erythroid enhancer impairs transcription of enhancer-driven RNAs and NIPBL-dependent cohesin loading, leading to the destabilization of the rosette structure, loss of chromatin insulation, and epigenetic silencing of BCL11A. Moreover, targeted depletion of enhancer RNAs using antisense oligonucleotides silences BCL11A by disrupting epigenetic insulation, causing HbF reactivation in adult erythroid cells. These findings uncover an essential role for enhancer-driven epigenetic insulation in transcriptional control, presenting a new strategy for the therapeutic targeting of BCL11A.
- 26 March 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (13) , 1470-1484
Top Cited PapersOpen AccessSilencing of BCL11A by disrupting enhancer-dependent epigenetic insulation
The transcription factor BCL11A is a genetically and clinically validated regulator of the fetal-to-adult hemoglobin switch in human erythroid cells. CRISPR editing of an intronic enhancer within the BCL11A gene reactivates fetal hemoglobin (HbF) in adult erythroid cells, serving as the first CRISPR-based therapy for β-hemoglobinopathies. However, the molecular basis for the remarkable efficacy of CRISPR-mediated enhancer ablation remains elusive. Here, we describe a new genome architecture, an enhancer-dependent chromatin rosette, that is essential for epigenetic insulation and the developmentally regulated, hematopoietic lineage–specific expression of BCL11A. CRISPR-mediated disruption of the BCL11A erythroid enhancer impairs transcription of enhancer-driven RNAs and NIPBL-dependent cohesin loading, leading to the destabilization of the rosette structure, loss of chromatin insulation, and epigenetic silencing of BCL11A. Moreover, targeted depletion of enhancer RNAs using antisense oligonucleotides silences BCL11A by disrupting epigenetic insulation, causing HbF reactivation in adult erythroid cells. These findings uncover an essential role for enhancer-driven epigenetic insulation in transcriptional control, presenting a new strategy for the therapeutic targeting of BCL11A.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
TableS2 from Enhancer Coamplification and Hijacking Promote Oncogene Expression in Liposarcoma
H3K27Ac ChIP-seq Patient Sample Statistics
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTableS2 from Enhancer Coamplification and Hijacking Promote Oncogene Expression in Liposarcoma
H3K27Ac ChIP-seq Patient Sample Statistics
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
TableS4 from Enhancer Coamplification and Hijacking Promote Oncogene Expression in Liposarcoma
Patient Sample WGS data statistics
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTableS4 from Enhancer Coamplification and Hijacking Promote Oncogene Expression in Liposarcoma
Patient Sample WGS data statistics
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
TableS1 from Enhancer Coamplification and Hijacking Promote Oncogene Expression in Liposarcoma
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTableS1 from Enhancer Coamplification and Hijacking Promote Oncogene Expression in Liposarcoma
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
TableS5 from Enhancer Coamplification and Hijacking Promote Oncogene Expression in Liposarcoma
Sequence Data Information in Lipo863B
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTableS5 from Enhancer Coamplification and Hijacking Promote Oncogene Expression in Liposarcoma
Sequence Data Information in Lipo863B
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Enhancer Coamplification and Hijacking Promote Oncogene Expression in Liposarcoma
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Enhancer Coamplification and Hijacking Promote Oncogene Expression in Liposarcoma
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
TableS3 from Enhancer Coamplification and Hijacking Promote Oncogene Expression in Liposarcoma
Patient Sample Hi-C data Statistics
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTableS3 from Enhancer Coamplification and Hijacking Promote Oncogene Expression in Liposarcoma
Patient Sample Hi-C data Statistics
- Open Access
- 14 March 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (11) , eadn2830
Spatial 3D genome organization reveals intratumor heterogeneity in primary glioblastoma samples
Glioblastoma (GBM) is the most prevalent malignant brain tumor with poor prognosis. Although chromatin intratumoral heterogeneity is a characteristic feature of GBM, most current studies are conducted at a single tumor site. To investigate the GBM-specific 3D genome organization and its heterogeneity, we conducted Hi-C experiments in 21 GBM samples from nine patients, along with three normal brain samples. We identified genome subcompartmentalization and chromatin interactions specific to GBM, as well as extensive intertumoral and intratumoral heterogeneity at these levels. We identified copy number variants (CNVs) and structural variations (SVs) and demonstrated how they disrupted 3D genome structures. SVs could not only induce enhancer hijacking but also cause the loss of enhancers to the same gene, both of which contributed to gene dysregulation. Our findings provide insights into the GBM-specific 3D genome organization and the intratumoral heterogeneity of this organization and open avenues for understanding this devastating disease.
- 14 March 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (11) , eadn2830
Open AccessSpatial 3D genome organization reveals intratumor heterogeneity in primary glioblastoma samples
Glioblastoma (GBM) is the most prevalent malignant brain tumor with poor prognosis. Although chromatin intratumoral heterogeneity is a characteristic feature of GBM, most current studies are conducted at a single tumor site. To investigate the GBM-specific 3D genome organization and its heterogeneity, we conducted Hi-C experiments in 21 GBM samples from nine patients, along with three normal brain samples. We identified genome subcompartmentalization and chromatin interactions specific to GBM, as well as extensive intertumoral and intratumoral heterogeneity at these levels. We identified copy number variants (CNVs) and structural variations (SVs) and demonstrated how they disrupted 3D genome structures. SVs could not only induce enhancer hijacking but also cause the loss of enhancers to the same gene, both of which contributed to gene dysregulation. Our findings provide insights into the GBM-specific 3D genome organization and the intratumoral heterogeneity of this organization and open avenues for understanding this devastating disease.
- Open Access
- 7 February 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (6) , eads4985
Pioneer factor GATA6 promotes colorectal cancer through 3D genome regulation
Colorectal cancer (CRC) is one of the most lethal and prevalent malignancies. While the overexpression of pioneer factor GATA6 in CRC has been linked with metastasis, its role in genome-wide gene expression dysregulation remains unclear. Through studies of primary human CRC tissues and analysis of the TCGA data, we found that GATA6 preferentially binds at CRC-specific active enhancers, with enrichment at enhancer-promoter loop anchors. GATA6 protein also physically interacts with CTCF, suggesting its critical role in 3D genome organization. The ablation of GATA6 through AID and CRISPR systems severely impaired cancer cell clonogenicity and proliferation. Mechanistically, GATA6 knockout induced global loss of CRC-specific open chromatins and extensive alterations of critical enhancer-promoter interactions for CRC oncogenes. Last, we showed that GATA6 knockout greatly reduced tumor growth and improved survival in mice. Together, we revealed a previously unidentified mechanism by which GATA6 contributes to the pathogenesis of colorectal cancer.
- 7 February 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (6) , eads4985
Open AccessPioneer factor GATA6 promotes colorectal cancer through 3D genome regulation
Colorectal cancer (CRC) is one of the most lethal and prevalent malignancies. While the overexpression of pioneer factor GATA6 in CRC has been linked with metastasis, its role in genome-wide gene expression dysregulation remains unclear. Through studies of primary human CRC tissues and analysis of the TCGA data, we found that GATA6 preferentially binds at CRC-specific active enhancers, with enrichment at enhancer-promoter loop anchors. GATA6 protein also physically interacts with CTCF, suggesting its critical role in 3D genome organization. The ablation of GATA6 through AID and CRISPR systems severely impaired cancer cell clonogenicity and proliferation. Mechanistically, GATA6 knockout induced global loss of CRC-specific open chromatins and extensive alterations of critical enhancer-promoter interactions for CRC oncogenes. Last, we showed that GATA6 knockout greatly reduced tumor growth and improved survival in mice. Together, we revealed a previously unidentified mechanism by which GATA6 contributes to the pathogenesis of colorectal cancer.